ARTICLE | Company News
Leiden University, Bellicum deal
June 1, 2015 7:00 AM UTC
The university granted Bellicum exclusive, worldwide rights to high-affinity T cell receptor (TCR) products targeting solid tumors expressing the preferentially expressed antigen in melanoma (PRAME)...